Cavernous neurotomy in the rat is associated with the onset of an overt condition of hypogonadism.

ABSTRACT Background Most men following radical retropubic prostatectomy (RRP) are afflicted by erectile dysfunction (ED). RRP-related ED occurs as a result of surgically elicited neuropraxia, leading to histological changes in the penis, including collagenization of smooth muscle and endothelial damage. Aim To verify whether hypogonadism could contribute to the pathogenesis of RRP-ED. Methods Effects of testosterone (T), alone or in association with long-term tadalafil (Tad) treatment in a rat model of bilateral cavernous neurotomy (BCN). Main Outcome Measures Penile tissues from rats were harvested for vasoreactivity studies 3 months post-BCN. Penile oxygenation was evaluated by hypoxyprobe immunostaining. Phosphodiesterase type 5 (PDE5), endothelial nitric oxide synthase (eNOS), and neuronal nitric oxide synthase (nNOS) mRNA expression were quantified by Real Time quantitative reverse transcription polymerase chain reaction (qRT-PCR). Results In BCN rats, we observed the onset of an overt condition of hypogonadism, characterized by reduced T plasma level, reduced ventral prostate weight, reduced testis function (including testis weight and number of Leydig cells), with an inadequate compensatory increase of luteinizing hormone. BCN induced massive penile hypoxia, decreased muscle/fiber ratio, nNOS, eNOS, PDE5 expression, increased sensitivity to the nitric oxide donor, sodium nitroprusside (SNP), and reduced the relaxant response to acetylcholine (Ach), as well as unresponsiveness to acute Tad dosing. In BCN rats, chronic Tad-administration normalizes penile oxygenation, smooth muscle loss, PDE5 expression, SNP sensitivity, and the responsiveness to the acute Tad administration. Chronic Tad treatment was ineffective in counteracting the reduction of nNOS and eNOS expression, along with Ach responsiveness. T supplementation, in combination with Tad, reverted some of the aforementioned alterations, restoring smooth muscle content, eNOS expression, as well as the relaxant response of penile strips to Ach, but not nNOS expression. Conclusion BCN was associated with hypogonadism, probably of central origin. T supplementation in hypogonadal BCN rats ameliorates some aspects of BCN-induced ED, including collagenization of penile smooth muscle and endothelial dysfunction, except surgically induced altered nNOS expression. Vignozzi L, Filippi S, Morelli A, Marini M, Chavalmane A, Fibbi B, Silvestrini E, Mancina R, Carini M, Vannelli GB, Forti G, and Maggi M. Cavernous neurotomy in the rat is associated with the onset of an overt condition of hypogonadism. J Sex Med 2009;6:1270–1283.

[1]  M. Averbeck,et al.  Androgen replacement in men undergoing treatment for prostate cancer. , 2008, The journal of sexual medicine.

[2]  A. Traish,et al.  The dark side of testosterone deficiency: I. Metabolic syndrome and erectile dysfunction. , 2008, Journal of andrology.

[3]  A. Burnett,et al.  Cavernous nerve injury using rodent animal models. , 2008, The journal of sexual medicine.

[4]  Wadih Arap,et al.  Quality of life and satisfaction with outcome among prostate-cancer survivors. , 2008, The New England journal of medicine.

[5]  L. Levine,et al.  Return of nocturnal erections and erectile function after bilateral nerve-sparing radical prostatectomy in men treated nightly with sildenafil citrate: subanalysis of a longitudinal randomized double-blind placebo-controlled trial. , 2008, The journal of sexual medicine.

[6]  J. Benites,et al.  Time course of endocrine changes in the hypophysis-gonad axis induced by hypobaric hypoxia in male rats. , 2008, The Journal of reproduction and development.

[7]  G. Forti,et al.  Which patients with sexual dysfunction are suitable for testosterone replacement therapy? , 2007, Journal of endocrinological investigation.

[8]  Anthony V D'Amico,et al.  Erectile function outcome reporting after clinically localized prostate cancer treatment. , 2007, The Journal of urology.

[9]  Run Wang Penile rehabilitation after radical prostatectomy: where do we stand and where are we going? , 2007, The journal of sexual medicine.

[10]  J. Mulhall,et al.  Penile rehabilitation should become the norm for radical prostatectomy patients. , 2007, The journal of sexual medicine.

[11]  G. Vannelli,et al.  Effect of sildenafil administration on penile hypoxia induced by cavernous neurotomy in the rat , 2007, International Journal of Impotence Research.

[12]  M. Sarosdy Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy , 2007, Cancer.

[13]  A. Traish,et al.  Are androgens critical for penile erections in humans? Examining the clinical and preclinical evidence. , 2006, The journal of sexual medicine.

[14]  C. Crescioli,et al.  ORIGINAL RESEARCH—BASIC SCIENCE: Effect of Chronic Tadalafil Administration on Penile Hypoxia Induced by Cavernous Neurotomy in the Rat , 2006 .

[15]  Xin-hua Zhang,et al.  Testosterone restores diabetes-induced erectile dysfunction and sildenafil responsiveness in two distinct animal models of chemical diabetes. , 2006, The journal of sexual medicine.

[16]  L. Vignozzi,et al.  Peripheral regulatory mechanisms in erection. , 2005, International journal of andrology.

[17]  F. Montorsi,et al.  Efficacy of sildenafil citrate in men with erectile dysfunction following radical prostatectomy: a systematic review of clinical data. , 2005, The journal of sexual medicine.

[18]  Philip S Li,et al.  The functional and structural consequences of cavernous nerve injury are ameliorated by sildenafil citrate. , 2005, The journal of sexual medicine.

[19]  F. Montorsi,et al.  Vardenafil for the treatment of erectile dysfunction: a critical review of the literature based on personal clinical experience. , 2005, European urology.

[20]  G. Vannelli,et al.  Testosterone regulates PDE5 expression and in vivo responsiveness to tadalafil in rat corpus cavernosum. , 2005, European urology.

[21]  F. Montorsi,et al.  Expression and functional activity of phosphodiesterase type 5 in human and rabbit vas deferens. , 2005, Molecular human reproduction.

[22]  P. Agarwal,et al.  Testosterone replacement therapy after primary treatment for prostate cancer. , 2005, The Journal of urology.

[23]  L. Levine Erectile dysfunction following treatment of prostate cancer: new insights and therapeutic options , 2004 .

[24]  J. Kaufman,et al.  Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. , 2004, The Journal of urology.

[25]  F. Montorsi,et al.  Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: a randomized, double-blind, placebo controlled trial. , 2004, The Journal of urology.

[26]  M. Giorgi,et al.  Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. , 2004, Endocrinology.

[27]  S. Gelmini,et al.  Oxytocin receptor is expressed in the penis and mediates an estrogen-dependent smooth muscle contractility. , 2004, Endocrinology.

[28]  K. Bennewith,et al.  Orally administered pimonidazole to label hypoxic tumor cells. , 2002, Cancer research.

[29]  P. Lavie,et al.  Decreased pituitary-gonadal secretion in men with obstructive sleep apnea. , 2002, The Journal of clinical endocrinology and metabolism.

[30]  F. Trimarchi,et al.  Sexual inactivity results in reversible reduction of LH bioavailability , 2002, International Journal of Impotence Research.

[31]  W. Catalona,et al.  Quality‐of‐life outcomes for men with prostate carcinoma detected by screening , 2000, Cancer.

[32]  R A Stephenson,et al.  Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. , 2000, JAMA.

[33]  K. Syrjala,et al.  Prevalence and predictors of sexual dysfunction in long-term survivors of marrow transplantation. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  J. Raleigh,et al.  Identification of nonproliferating but viable hypoxic tumor cells in vivo. , 1998, Cancer research.

[35]  D. Chan,et al.  Influence of radical prostatectomy on serum hormone levels. , 1998, The Journal of urology.

[36]  RB Moreland,et al.  Is there a role of hypoxemia in penile fibrosis: a viewpoint presented to the Society for the Study of Impotence , 1998, International Journal of Impotence Research.

[37]  F. Montorsi,et al.  Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: results of a prospective, randomized trial. , 1997, The Journal of urology.

[38]  R H Brook,et al.  Quality-of-life outcomes in men treated for localized prostate cancer. , 1995, JAMA.

[39]  I. Goldstein,et al.  Oxygen tension regulates the nitric oxide pathway. Physiological role in penile erection. , 1993, The Journal of clinical investigation.

[40]  A W Partin,et al.  The rat as a model for the study of penile erection. , 1989, The Journal of urology.

[41]  D. Rodbard,et al.  Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. , 1978, The American journal of physiology.

[42]  C. Huggins,et al.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate , 1941, CA: a cancer journal for clinicians.

[43]  D. Bodurka,et al.  Quality of Life and Sexual Functioning , 2006 .

[44]  Adrian L. Harris,et al.  Hypoxia — a key regulatory factor in tumour growth , 2002, Nature Reviews Cancer.

[45]  S. Pignata,et al.  Quality of life: gynaecological cancers. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.